论文部分内容阅读
目的分析那格列奈联合门冬胰岛素30治疗单独胰岛素控制不良的2型糖尿病的临床疗效。方法对单独使用胰岛素治疗效果不佳的46例2型糖尿病患者,按照0.5～2mg/次的剂量服用那格列奈,3次/日,分别于餐前15min口服。晚餐前服药时,联合使用门冬胰岛素30进行皮下注射,并于3d内视患者情况调整药量继续治疗。另外,对患者在2hPG、FBG、HbA1c方面的治疗效果,以及治疗后的不良反应情况作出分析。结果使用那格列奈联合门冬胰岛素30方式,较之前患者单独使用胰岛素治疗方式,在2hPG、FBG、HbA1c方面治疗后较治疗前出现更大幅度下降。另外,所有患者治疗后肝肾功能均未出现异常,1例患者出现低血糖反应。结论对于单独胰岛素控制不良的2型糖尿病采用那格列奈联合门冬胰岛素30的方式治疗,临床效果显著,不良反应小,值得推广。
Objective To analyze the clinical efficacy of nateglinide combined with insulin aspart 30 in the treatment of type 2 diabetes with poorly controlled insulin. Methods Forty-six patients with type 2 diabetes who did not receive insulin alone were treated with nateglinide at dose of 0.5-2 mg / time and orally three times daily at 15 minutes before meals. Medication before dinner, the combination of insulin aspart 30 for subcutaneous injection, and in the 3d according to the patient’s condition to adjust the dose to continue treatment. In addition, the patients in the 2hPG, FBG, HbA1c aspects of the treatment effect, and the adverse reactions after treatment to make an analysis. Results The nateglinide combined with aspart insulin 30 approach showed a more significant reduction than before treatment in 2hPG, FBG and HbA1c compared with insulin therapy alone. In addition, all patients had no abnormal liver and kidney function after treatment, and 1 patient had hypoglycemia. Conclusion Treatment of nateglinide combined with aspart 30 in type 2 diabetes with poorly controlled insulin alone has significant clinical effect and small adverse reactions and is worth promoting.